Keyword Analysis & Research: baricitinib
Keyword Research: People who searched baricitinib also searched
Search Results related to baricitinib on Search Engine
-
Baricitinib - Wikipedia
https://en.wikipedia.org/wiki/Baricitinib
WEBBaricitinib, sold under the brand name Olumiant among others, is an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.
DA: 90 PA: 10 MOZ Rank: 36
-
Baricitinib (Olumiant): Uses, Dosage, Side Effects, Warnings - Drugs.com
https://www.drugs.com/baricitinib.html
WEBMay 7, 2024 · Baricitinib (Olumiant) is an oral Janus kinase (JAK) inhibitor that may be used to treat adults with: moderately to severely active rheumatoid arthritis (RA) who have not had a good response to one or more TNF blockers.
DA: 66 PA: 46 MOZ Rank: 96
-
Baricitinib - StatPearls - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK572064/
WEBJan 10, 2024 · Baricitinib medication is approved by the U.S. Food and Drug Administration (FDA) to treat adult patients with moderately to severely active rheumatoid arthritis who have not responded adequately to other DMARDs, including tumor necrosis factor (TNF) antagonist therapies.
DA: 61 PA: 61 MOZ Rank: 99
-
Olumiant® (baricitinib) - Rheumatoid Arthritis (RA) & Alopecia …
https://olumiant.lilly.com/
WEBOlumiant® (O-loo-mē-ant) is a Janus kinase (JAK) inhibitor used to treat: adults with severe alopecia areata. adults with moderately to severely active rheumatoid arthritis after treatment with 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well enough or could not be tolerated.
DA: 35 PA: 15 MOZ Rank: 23
-
Baricitinib: Uses & Side Effects - Cleveland Clinic
https://my.clevelandclinic.org/health/drugs/21394-baricitinib-oral-tablets
WEBWhat is this medication? BARICITINIB (BAR i SYE it nib) treats rheumatoid arthritis. It may be used to treat severe hair loss. It can also be used to treat COVID-19. This medication works on the immune system. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.
DA: 27 PA: 34 MOZ Rank: 25
-
Baricitinib (Oral Route) Description and Brand Names - Mayo Clinic
https://www.mayoclinic.org/drugs-supplements/baricitinib-oral-route/description/drg-20487070
WEBMay 1, 2024 · Baricitinib is a Janus kinase (JAK) inhibitor that works on the immune system. This medicine is available only with your doctor's prescription for rheumatoid arthritis. This medicine is to be given only by or under the immediate supervision of your doctor for COVID-19.
DA: 12 PA: 43 MOZ Rank: 20
-
FDA Approves First Systemic Treatment for Alopecia Areata
https://www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata
WEBFor Immediate Release: June 13, 2022. Español. Today, the U.S. Food and Drug Administration approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata, a...
DA: 57 PA: 24 MOZ Rank: 65
-
What is Olumiant® for RA & How it Works | Olumiant® (baricitinib)
https://olumiant.lilly.com/rheumatoid-arthritis/what-is-olumiant
WEBDiscover how Olumiant® (baricitinib) works as a Janus kinase (JAK) inhibitor. Learn more about talking to your doctor and finding a rheumatologist.
DA: 25 PA: 66 MOZ Rank: 5
-
Baricitinib: MedlinePlus Drug Information
https://medlineplus.gov/druginfo/meds/a618033.html
WEBBaricitinib is used alone or with other medications to treat rheumatoid arthritis (condition in which the body attacks its own joints causing pain, swelling, and loss of function) in adults who have not responded well to one or more tumor …
DA: 89 PA: 12 MOZ Rank: 100
-
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323235/
WEBJul 27, 2020 · Baricitinib is a reversible Janus‐associated kinase (JAK)‐inhibitor that interrupts the signaling of multiple cytokines implicated in COVID‐19 immunopathology. It may also have antiviral effects by targeting host factors that viruses rely for cell entry and by suppressing type I interferon driven angiotensin‐converting‐enzyme‐2 upregulation.
DA: 30 PA: 36 MOZ Rank: 29